Summary
Plasma concentrations of aprindine were used to assess its absorption, toxicity and disappearance rate after oral administration to patients within 24 hours of admission to a coronary care unit. Despite high oral doses, absorption was so slow that in half the patients effective plasma levels (exceeding 0.70 µg/ml) were not found during the first 12 hours of treatment. Therefore the oral route should not be used to treat cases of acute myocardial infarction with severe ventricular dysrhythmias. Clinical tolerance was good; there was one episode of delirium tremens in a chronic alcoholic (aprindine plasma concentration: 3 µg/ml); no case of tremor or cerebellar syndrome was observed. Disappearance of aprindine from plasma was slow, by far exceeding the half-lives found in healthy volunteers, and ranging from 20 to over 100 h. The variability of biological half-life in individual patients makes plasma level determinations necessary whenever aprindine is to be administered for a long period.
Similar content being viewed by others
References
Bloomfield, S.S., Romhilt, D.W., Chou, T.C., Fowler, N.O.: Quinidine for prophylaxis of arrhytmias in acute myocardial infarction. New Engl. J. Med.285 979–986 (1971)
Campbell, N.P.S., Chaturvedi, N.C., Kelly, J.G., Strong, J.E., Shanks, R.G., Pantridge, J.F.: Mexiletine (Kö 1173) in the mangement of ventricular dysrhythmias. Lancet1973 II 404–407
Carmeliet, E., Verdonck, F.: Effects of aprindine and lidocaine on transmembrane potentials and radioactive K efflux in different cardiac tissues. Acta cardiol. (Brux.) suppl. XVIII, 73–90 (1974)
Delcroix, C., Martin, L., Van Durme, J.P., Kesteloot, H., Hagemeijer, F., Mbuyamba, P., Deblecker, M.: Model for exchange kinetics of aprindine in man after single and multiple doses. Acta cardiol. (Brux.) suppl. XVIII, 177–194 (1974)
Dodion, L., De Suray, J.M., Deblecker, M., Georges, A.: Caractéristiques pharmacocinétiques et biodégradation de l'aprindine chez l'homme. Thérapie29 221–232 (1974)
Georges, A., Hosslet, A., Duvernay, G.: Pharmacological evaluation of aprindine (AC 1802), a new antiarrhythmic agent. Acta cardiol. (Brux.)28 166–191 (1973)
Greenspan, K., Steinberg, M., Holland, D., Freeman, A.R.: Electrophysiologic alterations in cardiac dysrhythmias: antiarrhythmic effects of aprindine. Amer. J. Cardiol.33 140 (1974)
Hackett, T.P., Cassem, N.H., Wishnie, H.A.: The coronary care unit. An appraisal of its psychologic hazards. New Engl. J. Med.279 1365–1370 (1968)
Kesteloot, H., Van Mieghem, W., De Geest, H.: Aprindine (AC 1802), a new anti-arrhythmic drug. Acta cardiol. (Brux.)28 145–165 (1973)
Koch-Weser, J., Klein, S.W., Foo-Canto, L.L.: Antiarrhythmic prophylaxis with procaineamide in acute myocardial infarction. New Engl. J. Med.281 1253–1260 (1969)
Koch-Weser, J.: Pharmacokinetics of procainamide in man. Ann. N.Y. Acad. Sci.179 370–382 (1971)
Lie, K.I., Wellens, H.J., Van Capelle, F.J., Durrer, D.: Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients. New Engl. J. Med.291 1324–1326 (1974)
Lovell, R.R.H., Prineas, R.J.: Mechanisms of sudden death and their implications for prevention and management. Progr. cardiovasc. Dis.13 482–494 (1971)
Pitt, A., Lipp, H., Anderson, S.T.: Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet1971 I 612–616
Singh, B.N., Hauswirth, O.: Comparative mechanisms of action of antiarrhythmic drugs. Amer. Heart J.87 367–382 (1974)
Talbot, R.G., Clark, R.A., Nimmo, J., Neilson, J.M.M., Julian, D.G., Prescott, J.F.: Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet1973 II 399–404
Van Durme, J.P., Bogaert, M.G., Rosseel, M.T.: Therapeutic effectiveness and plasma levels of aprindine, a new antidysrhythmic drug. Europ. J. clin. Pharmacol.7 343–346 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hagemeijer, F. Absorption, half-life, and toxicity of oral aprindine in patients with acute myocardial infarction. Eur J Clin Pharmacol 9, 21–25 (1975). https://doi.org/10.1007/BF00613425
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613425